Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus (Nasdaq: SLP) has announced a new collaboration with a major pharmaceutical company to enhance its GastroPlus® Advanced Compartmental Absorption and Transit (ACAT™) model for oral peptide formulations. The project aims to improve intestinal absorption simulations for larger molecules, utilizing unique data from the partner. This partnership aligns with the growing demand for oral therapeutic peptides, expanding the company's modeling capabilities. All enhancements will be available to SLP’s user community, aiming to accelerate drug development timelines.
Simulations Plus, Inc. (Nasdaq: SLP) will report its financial results for the first quarter of fiscal year 2021 after the market closes on January 11, 2021. A conference call will follow at 4:15 p.m. Eastern Time, inviting all interested parties to join by registering online or via phone. The call will also be available as a live webcast. Simulations Plus specializes in modeling and simulation software for drug discovery and development, with its technology used by several major pharmaceutical and biotechnology companies worldwide.
Summary not available.
DILIsym Services, a subsidiary of Simulations Plus (Nasdaq: SLP), presented key research at the 2020 AASLD virtual Liver Meeting, showcasing their modeling software applications for drug safety and efficacy. Notable studies included the liver safety profile of remdesivir and the role of adiponectin in treating non-alcoholic fatty liver diseases, utilizing DILIsym and NAFLDsym software. These presentations emphasize the company’s commitment to advancing pharmaceutical collaborations and improving drug development processes.
Simulations Plus, Inc. (Nasdaq: SLP) has appointed Will Frederick as its new chief financial officer (CFO), succeeding John Kneisel who retires after seven years. Frederick brings over 25 years of experience in financial leadership, with a focus on revenue growth and corporate strategy. CEO Shawn O’Connor praised Frederick’s background, highlighting his previous experience in mergers and public company CFO roles. The company has a strong history under Kneisel, achieving consistent revenue growth and three successful acquisitions.
Simulations Plus reported a strong FY20 with revenues of $41.6 million, up 22.4% from FY19. Gross profit increased 24.0% to $30.9 million. Net income rose 8.7% to $9.3 million, boosting diluted EPS to $0.50. For 4QFY20, revenues climbed 18.9% to $9.5 million, with net income at $2.2 million. The company raised $107.7 million through a follow-on offering, enhancing resources for acquisitions. CEO Shawn O’Connor highlighted robust growth amidst the pandemic, driven by software and consulting services.
Simulations Plus (Nasdaq: SLP) announced that its DILIsym liver safety software contributed to public comments to the California Office of Environmental Health Hazard Assessment (OEHHA) regarding the carcinogenicity of acetaminophen (APAP). The Consumer Healthcare Products Association utilized DILIsym's simulations, which indicated that while high doses of APAP can pose acute liver toxicity, they do not lead to cancer. The FDA's comments supported these findings. DILIsym's modeling aids in drug development decisions, minimizing risks associated with drug-induced liver injury.
Simulations Plus, Inc. (Nasdaq: SLP) announced it will report its fourth quarter and full year financial results for fiscal year 2020 on November 16, 2020, after market close. The company will host a conference call at 4:15 p.m. ET on the same day, allowing interested parties to participate by registering online. Simulations Plus specializes in drug discovery and development software and consulting services, aiding pharmaceutical and biotechnology companies in the regulatory submission process.
Simulations Plus, a leader in simulation and modeling software for pharmaceutical development, announced that CEO Shawn O'Connor will present at the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10, 2020, at 3:30 p.m. ET. His presentation will be available via a live webcast, and a slide presentation can be accessed on the company's Investors page afterwards. Simulations Plus provides advanced modeling solutions utilized by major pharmaceutical and regulatory agencies worldwide.
Simulations Plus (Nasdaq: SLP), through its subsidiary Lixoft, has announced the release of MonolixSuite version 2020R1, enhancing population PKPD modeling solutions. Key improvements include an upgraded Simulx module with a user-friendly GUI, new dataset filters, a tumor growth inhibition library, and advanced capabilities for non-compartmental analysis (NCA). These updates aim to streamline modeling and simulation processes in drug development. Lixoft emphasizes user experience and advanced statistical methods that align with industry demands.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
